Table 4.
Association of main baseline characteristics of RA patients with rapid radiographic progression at 2 years (univariate analysis)
| ΔM24–M0 total mSharp >10 | P value | OR (95 % CI) | ΔM24–M0 erosion mSharp > 5 | P value | OR (95 % CI) | ΔM24–M0 joint-space narrowing mSharp >5 | P value | OR (95 % CI) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | |||||||
| Age | 51.5 ± 10.7 | 48.2 ± 11.8 | 0.059 | 1.03 (0.99–1.05) | 51.8 ± 8.9 | 48.4 ± 11.8 | 0.108 | 1.03 (0.99–1.06) | 49.4 ± 11.4 | 48.4 ± 11.7 | 0.471 | 1.01 (0.98–1.03) |
| Female (%) | 84.6 | 81.1 | 0.543 | 0.78 (0.35–1.74) | 87.5 | 81.0 | 0.367 | 1.64 (0.56–4.83) | 83.5 | 80.9 | 0.571 | 1.19 (0.65–2.20) |
| BMI | 25.9 ± 4.9 | 25.3 ± 4.6 | 0.245 | 1.04 (0.98–1.10) | 25.1 ± 4.9 | 25.3 ± 4.6 | 0.866 | 0.99 (0.927–1.08) | 25.6 ± 4.7 | 25.2 ± 4.6 | 0.447 | 1.02 (0.97–1.07) |
| RF (%) | 69.2 | 48.2 | 0.005 | 2.42 (1.29–4.53) | 78.1 | 41.7 | 0.005 | 3.14 (1.37–7.18) | 64.9 | 46.3 | 0.002 | 2.15 (1.33–3.47) |
| ACPA (%) | 65.4 | 41.5 | 0.001 | 2.67 (1.45–4.92) | 75.0 | 48.9 | 0.005 | 5.0 (2.106–11.872) | 59.8 | 39.6 | 0.001 | 2.271 (1.418–3.635) |
| Total mSharp score | 4.0 ± 4.8 | 3.7 ± 4.4 | 0.644 | 1.10 (0.95–1.08) | 4.5 ± 5.0 | 3.7 ± 4.4 | 0.341 | 1.04 (0.96–1.12) | 3.8 ± 4.8 | 3.7 ± 4.3 | 0.837 | 1.01 (0.95–1.06) |
| DAS28(ESR)-4v | 5.5 ± 1.4 | 5.3 ± 1.1 | 0.211 | 1.2 (0.9–1.5) | 5.5 ± 1.5 | 5.3 ± 1.2 | 0.331 | 1.16 (0.86–1.59) | 5.3 ± 1.3 | 5.3 ± 1.1 | 0.784 | 1.03 (0.84–1.25) |
| logCRP level | 1.25 ± 0.51 | 0.98 ± 0.46 | 0.000 | 3.3 (1.8–6.3) | 1.25 ± 0.49 | 1.00 ± 0.47 | 0.004 | 1.01 (1.00–1.02) | 1.16 ± 0.47 | 0.96 ± 0.46 | 0.001 | 2.414(1.445–4.03) |
| ESR | 35 ± 26 | 28 ± 24 | 0.009 | 1.01 (1.00–1.02) | 36 ± 29 | 28 ± 24 | 0.016 | 1.01 (1.00–1.02) | 32 ± 25 | 26 ± 21 | 0.030 | 1.01 (1.00–1.02) |
| Steroid use (%) | 19.2 | 13.4 | 0.264 | 0.651 (0.305–1.390) | 8.0 | 13.4 | 0.413 | 1.66 (0.49–5.65) | 83.5 | 86.6 | 0.455 | 0.785 (0.416–1.483) |
| cDMARD use (%) | 89.6 | 82.2 | 0.210 | 1.86 (0.71–4.91) | 85.2 | 83 | 0.774 | 1.18 (0.39–3.53) | 90.2 | 80.8 | 0.041 | 2.19 (1.03–4.64) |
| logOPG/TRAIL ratio Q <25 (%) | 23.5 | 25.6 | 0.894 (0.447–1.787)a | 12.9 | 26.4 | 0.412 (0.140–1.210)a | 26.0 | 25.1 | 1.051 (0.619–1.785)a | |||
| LogGPG/TRAIL ratio Q25–75 (%) | 47.1 | 50.6 | 0.685 | 45.2 | 50.6 | 0.041 | 53.1 | 49.1 | 0.614 | |||
| logOPG/TRAIL ratio Q >75 (%) | 29.4 | 23.8 | 1.335 (0.695–2.568)b | 41.9 | 23.0 | 2.419 (1.136–5.152)b* | 20.8 | 25.8 | 0.757 (0.432–1.325)b | |||
Data are mean ± SD (median) or percentage. Significant values are in bold
RA rheumatoid arthritis, M month, mSharp score van der Heijde-modified Sharp score, OR odds ratio, 95 % CI, 95 % confidence interval, BMI body mass index, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, DAS28(ESR)-4v Disease Activity Score in 28 joints, calculated with erythrocyte sedimentation rate (ESR) and four values, CRP C-reactive protein, cDMARD conventional disease-modifying anti-rheumatic drug (used at least at two visits),, OPG osteoprotegerin, TRAIL tumor necrosis factor-related apoptosis-inducing ligand, Q <25 quartile <25th percentile, Q >75 quartile >75th percentile
*p <0.05 p value for comparison of aQ <25th versus Q ≥25th percentile and bQ >75th versus Q ≤75th percentile